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Abstract
The aim of this guidance is to provide recommendations to clinicians and other interested parties on chronic
urticaria in children. The Italian Society for Pediatrics (SIP), the Italian Society for Allergy and Immunology (SIAIP), the
Italian Society for Pediatric dermatology (SIDerP) convened a multidisciplinary panel that prepared clinical
guidelines for diagnosis and management of chronic urticaria in childhood. Key questions on epidemiology, natural
history, diagnosis, and management were developed. The literature was systematically searched and evaluated,
recommendations were rated and algorithms for diagnosis and treatment were developed. The recommendations
focus on identification of diseases and comorbidities, strategies to recognize triggering factors, improvement of
treatment by individualized care.
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Introduction
Chronic urticaria (CU) is characterized by recurrent migrat-
ing skin lesions, called wheals or hives, angioedema (AE) or
both lasting over 6 weeks. Wheals consist of a swelling area
of different size and shape with a larger erythema, often
pruritic. Lesions usually disappear in 24 h. In vasculitis and
pressure urticaria lesions persist longer.
AE is a submucosal or subcutaneous swelling, and in-
volves areas such as lips, eyelids, back of the hands and feet,
scrotum. AE resolves in 1–3 days and causes pain, tingling,
burning sensation or tension, but not itching. Prognosis
quoad vitam and quoad valetudinem of CU is generally
good. However, comorbidities can occur [1–4]. Overall, it
is a condition of mostly unknown etiopathogenesis, and a
frequent cause of specialist consultation and inappropriate
diagnostic investigation, aimed at identifying a causal factor
which is often not evident by history alone [4, 5].
Many guidelines on CU are available. None of them is
dedicated to the paediatric population and some differ-
ence occurs among guidelines [6–11]. Many documents
do not address specifically CU, whose etiopathogenesis
is believed to be different from acute urticaria (AU),
while many others discuss only chronic spontaneous ur-
ticaria (CSU) [10]. Therefore, the aim of the present
guideline is to provide an evidence-based approach for
the management of CU in children for use in clinical
practice.
Methods
In 2016, the Italian Society for Pediatrics (SIP), the
Italian Society for Allergy and Immunology (SIAIP), the
Italian Society for Pediatric dermatology (SIDerP)
convened a multidisciplinary panel that included pri-
mary care paediatricians, general pediatricians, hospital
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paediatricians, allergist, immunologist, dermatologist,
psychologist, methodologist skilled in systematic reviews
and guideline. No conflict of interest was declared by
panel members.
Team members defined the most relevant questions on
CU in childhood, then they agreed on systematic literature
research and literature evaluation strategy. Search strategy
aimed at gathering studies, published from June 1, 2009
that is the last year included in the previous SIAIP/SIP/
SIDerP guideline on CU [12], to January 1, 2018 concern-
ing prevalence, incidence, aetiology, diagnosis, therapy,
prognosis and psychological issues of CU in children.
The research was limited to studies published in English
and Italian, with no preferential type of study.
In order to select the studies to be included in the final
analysis, a hierarchic selection of literature sources was
chosen, starting from secondary sources (evidence-based
guidelines and systematic reviews) and proceeding with
primary studies (RCTs and non-randomized trials).
Guideline documents were searched in the main general
guideline websites and in the websites of the main scien-
tific societies pertinent to CU. Systematic reviews were
searched in Cochrane Database, DARE and Pubmed,
using keywords as “urticaria” or “chronic urticaria” and
“systematic review”. Evidence on primary studies was ob-
tained by literature searches of PubMed/EMBASE. In
PubMed, the following search strings and keywords were
used - (“Epidemiology”[Mesh] OR “Causality”[Mesh]) OR
“etiology”[Subheading]) OR “Prevalence”[Mesh]) OR
“Cross-Sectional Studies”[Mesh]) OR “Incidence”[Mesh])
OR (“Diagnosis”[Mesh]) OR “diagnosis” [Subheading] OR
(“Therapeutics”[Mesh]) OR “therapy” [Subheading] OR
(“Prognosis”[Mesh] OR (“psychol*”[All Fields] OR
“psychiatr*”[All Fields] OR “Depression”[Mesh] OR
“Depressive Disorder”[Mesh] OR “anxiet*”[All Fields] OR
“anx*”[All Fields] OR “Mood Disorders”[Mesh] OR
“Affective Disorders, Psychotic”[Mesh] OR “Mental
Disorders”[Mesh]) AND (“hives”[All Fields] OR “urticar-
ia”[All Fields] OR “Urticaria”[Mesh] OR “Angioedema”[-
Mesh] OR “chronic urticaria”[All Fields] OR “chronic
spontaneous urticaria”[All Fields] OR “chronic idiopathic
urticaria”[All Fields] AND ((“2009/06/01”[PDAT]: “2017/
12/31”[PDAT]) AND (“infant”[MeSH Terms] OR “child”[-
MeSH Terms] OR “adolescent”[MeSH Terms]) AND
(English [lang] OR Italian [lang]).
Appropriate changes have been made to search in
EMBASE: ‘chronic urticaria’/exp. AND ([english]/lim
OR [italian]/lim) AND ([infant]/lim OR [child]/lim OR
[preschool]/lim OR [school]/lim OR [adolescent]/lim)
AND [humans]/lim AND ([embase]/lim OR.
Other studies, with no restriction of type were found
through the electronic databases, references of the selected
studies, hand searches or papers suggested by experts were
also used.
Two authors have independently selected the stud-
ies relevant to each clinical question from the system-
atic research. They critically appraised each article,
using the following validated tools when appropriate:
SNLG criteria [13] and Grilli criteria [14] for Guide-
lines. AMSTAR tool [15] for Systematic reviews.
AMSTAR-2 [16] was not used, as it has been recently
published and its validity has not yet been verified.
Assessment of Risk of Bias tool from Cochrane Col-
laboration [17] for randomized controlled trials
(RCT). Newcastle-Ottawa scale for cohort studies,
case-control studies and cross-sectional studies, when
comparative [18] for observational studies. QUADAS-
2 [19] for diagnostic studies. Users’ Guides to the
Medical Literature [20] for prognostic studies. A
complete list of appraisals of selected papers is
available at http://www.siaip.it. Any disagreement in
evaluation has been resolved via discussion. An evi-
dence-based critical analysis was used to formulate
conclusions and recommendations. Expert consensus
was used when there was a lack of data. When it was
possible, it was provided a recommendation based on
grading of the quality of available evidence from the
literature according to the Italian National Guideline
(PNLG) method [13]. The criteria are as follows.
Level of evidence. I. Evidence obtained from more
than one properly designed randomized controlled
trial and/or systematic revision of randomized study.
II. Evidence obtained from one properly designed ran-
domized controlled trial.III. Evidence obtained from
non-randomized cohort studies with concurrent or
historical controls, or their metanalysis. IV. Evidence
obtained from retrospective case-control studies or
their metanalysis. V. Evidence obtained from case-
series with no control group. VI. Opinions of
respected authorities, group of experts as shown in
guidelines, consensus conferences or based on opinion
of members of the panel of the current guideline.
Strength of recommendation. A. Strong recommenda-
tion for performing diagnostic test or procedure, high
quality evidence even not necessarily of level I or II.
B. It is uncertain that diagnostic test or procedure
should be recommended but the intervention should
be carefully considered. C. Evidence not allowing rec-
ommendation for or against intervention. D. Perform-
ing diagnostic test or procedure is not recommended.
E. Strong advisement against performing diagnostic
test or procedure. Panel members reached agreement
on levels of evidence and strength of recommenda-
tions. Before approval, the guideline was reviewed by
nurses, parents, in order to consider the need for
health and the expectations of affected children and
their families, and experts who were identified by the
panel. All comments were considered in the final
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document when appropriate. The recommendations in
these guidelines will be disseminated through publish-
ing articles and promoting courses. The impact of the
current guideline on practice will be assessed by clin-
ical studies. The guideline will be updated after 5
years to maintain validity.
Question 1. What is the definition of CU, in the
paediatric age?
Answer. CU in paediatric age is defined by the daily
presence of wheals, that are not always associated with
angioedema, for over 6 weeks or with brief periods of
well-being due to therapy.
Urticaria, AE or both are defined as chronic when they
last for over 6 weeks. This definition allows to discrimin-
ate CU from AU, typically self-healing in a few days or
weeks [7, 8], usually caused by viral infections or IgE
mediated mechanisms. In a child with urticaria onset it
is not possible to establish in which cases it will last over
6 weeks. In the paediatric population no markers have
been identified [21]. Isolated AE is usually recurrent not
persisting.
Thus far, there is no reason to believe that CU with
AE is a different clinical entity from CU without AE,
although some studies on adults seem to suggest that
the presence of AE correlates with a higher chance of
positive autologous serum skin test (ASST) [22, 23].
Conversely, isolated AE without urticaria often involves
pathogenetic mechanisms and have clinical features that
are different from AE associated with CU [24]. There-
fore, it must be considered that isolated chronic AE
without urticaria should be distinguished from CU, espe-
cially in the process of differential diagnosis.
Question 2. What is the classification of CU?
Answer. CU in the child must be classified in
“spontaneous” or “inducible”, in relation to the
evidence of a triggering factor (Table 1).
In CSU, there is no eliciting factor. In chronic inducible
urticaria (CIU), one or more triggers, often physical
agents, can be identified by history and/or laboratory tests
[6, 8, 25]. Although “spontaneous” and “idiopathic” are
often used as interchangeable terms, the definition of CSU
is to be preferred as there is an anti-IgE autoantibody me-
diated form that should not be considered idiopathic.
However, separating CU associated with anti-IgE autoanti-
bodies from CSU [6] is not justified as many studies in
adults have not found any histological differences between
CSU and autoimmune CU [26]. Moreover, although some
studies in adults found that autoimmune CU can have a
more severe and prolonged course [27], there is no such
evidence in children [4, 28]. Finally, in adults, data suggest
that some forms of CIU may have an autoimmune mech-
anism [29, 30].
Question 3. What is the prevalence and incidence of
CU in the paediatric population?
Answer. Few data exist on epidemiology of urticaria in
children, however it is reasonable to think that
prevalence and incidence of CU in developmental age
are both below 1% (Level of evidence IV).
Few data are available on epidemiology of CU in
children. Studies on mixed adult and children
populations reported a lifetime prevalence of 0.8%
[31]. A Korean survey on children aged 4-13 found a
prevalence of 0,7%, with no difference among the two
sexes [32]. Concerning incidence, an Italian study on
children aged 0-14, where the diagnosis of CU was
made by a paediatrician, showed an annual incidence of
0.6 to 2.1 /1000 children, and a prevalence fluctuating
between 0,38% and 0,84% [33]. Overall, the
prevalence of CU in children seems to be below
1%, and there is no significant difference among
males and females [31–35].
Question 4. What is the natural history of CU in
paediatric age?
Answer. Remission at 3 years from onset of CSU in
children happens in 30% to 50% of cases. Anaphylaxis
is reported only in CIU (Level of evidence IV).
Prospective as well as retrospective studies of good
methodological quality on representative paediatric pop-
ulations showed that chance of remission of CSU at a
year from onset ranged from 10 to 32% [36–42]. At 3
years from onset, remission chance varied from 31 to
54% and at 5 years from 38 to 72%. The variability of the
percentages was due to the different duration of the ob-
servation period, different criteria to define remission
and sample size. A recent study reported a remission in-
cidence of 10.3% per year. In the same study, a positive
basophil activation test (BAT) or the lack of circulating
basophils were associated to an almost double chance of
remission after one year of follow-up [42].
The natural course of CU in children is therefore
not different from adults [43–45]. However, some
studies on adult and children samples have shown a
higher probability of improvement of symptoms in
subjects below 19 years old [46]. Female, age above
10 years and severe disease at onset have been
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related to a lesser chance of remission at 3–5 years of age
[38–41].
The natural course of physical factors induced CU and
cholinergic CU is not well known, but it is probably like
CSU [47–51]. Some studies, mainly performed on adults,
reported a more prolonged duration of disease in pa-
tients with cold urticaria [52, 53] and solar urticaria [54].
A longer persistence of CIU in atopic subjects compared
to non-atopic ones has been found [47].
Question 5. What is the etiopathogenesis of CU in
children?
Answer. In most cases, CU in children is spontaneous
and no external cause is found. However, in half of the
cases of CSU, an autoimmune mechanism is possible.
In a minority of patients, CU is associated with
inducing factors, often physical (Level of evidence V).
Pathogenesis of CU in children has been poorly in-
vestigated and studies have a low methodological
quality. A systematic review [55] and subsequent
studies [38, 41, 56] have showed that in most cases,
an external cause of CU is not identified. In a recent
survey, a potential cause has been found only in 8.8%
of children with CU [41]. Most studies in children
describe the frequency of factors associated with CU
that were considered as causal agents, without being
compared to a control population [36, 38, 41, 55–58].
Moreover, in most studies the association with a
causal factor was established without evaluating the
effectiveness of its removal (e.g. Infections, allergens).
So, the prevalence of each potential causative factor
varies among studies, even considering differences in
setting and diagnostic criteria [55]. In CSU, an auto-
immune pathogenesis has been reported in almost
half of the cases [38, 41, 55, 56].
• What is the role and the effect of inducing factors in
children?
Answer. Inducing factors are the most frequent and
often the only identifiable cause of CU in children
(Level of evidence V).
Inducing factors (Table 1) are usually the most fre-
quent cause of CU in children [36, 42, 55, 56, 58, 59].
The evidence of the role of inducing factors in children’s
CU has been confirmed by the reproduction of skin le-
sions when the relevant stimuli [25] are applied. In chil-
dren, inducing factors triggered CU in 6.2 to 52.9% of
cases [36, 55, 58–60]. In studies where inducing factors
were investigated following international guidelines, the
relative prevalence of CIU ranged from 22 to 40.1% of
cases [42, 56]. The discrepancy of prevalence is due to het-
erogeneity of population samples and different diagnostic
approaches. Dermographism, cholinergic urticaria and
cold urticaria are the most common [42, 47, 55, 56, 61].
Different types of CIU can coexist in the same subject
[25, 61, 62]. Moreover, in patients with CSU, hives may
develop following exposure to physical stimuli, mainly
dermographism and pressure [25, 61]. The pathogenesis
of CIU is unclear. Serum from affected subjects (e.g.
dermographism or cholinergic urticaria) injected into a
monkey passively transfers the symptoms [63]. More
recently, in patients with solar urticaria or cold urti-
caria, an IgE-mediated response against cutaneous, trig-
ger-released auto-allergens seems to be implied [64–
66]. Systemic symptoms such as bronchospasm,
hypotension, loss of conscience, intestinal wall oedema,
up to anaphylaxis and exitus may occur in solar urticaria,
cold urticaria, pressure urticaria, cholinergic urticaria and
aquagenic urticaria [29, 47–49, 52–54, 61, 64–69]. About
1/3 of patients with cold urticaria has had at least one
episode of anaphylaxis, most commonly after bath in
the sea or in the pool [52, 53, 65, 68]. In children, cold
urticaria is rarely due to cryoglobulinemia or parapro-
teinemia [52].
• What is the role of infections/infestations in
children’s CU?
Answer. The evidence on the role of viruses, bacteria
or parasites in inducing CU is sparse and limited to
single cases or case series. Few paediatric patients
with CU and parasitical infestations that healed after
the eradication of parasites have been described. This
correlation has been occasionally reported in other
infections (Level of evidence V).
Viral and bacterial infections have been reported to aggra-
vate [6] or cause [4, 7, 8, 70] CU in children with a frequency
Table 1 Classification of chronic urticaria
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ranging from 0 to 35% of patients with CU, while parasitical
infestations from 0 to 37.8% [36–39, 41, 42, 55–57, 71]. The
causal role of infections in patients with CU requires a high
incidence of the infection in affected patients, and remission
of symptoms after treatment [39, 57, 70, 71]. However, the
prevalence of chronic infections in patients with CU is not
different from the general population [8, 70]. Moreover, chil-
dren with CU, affected by chronic infections or parasitic
diseases, that are still symptomatic after eradication therapy
have commonly been reported [42, 56]. These findings sug-
gest that the association between infection and CU is mostly
accidental [8] and that in many cases CU recovers because of
the disease’s natural course rather than because of the treat-
ment of the infection.
Bacteria are the most studied, particularly Helicobacter
pylori. Protein components of H. pylori of molecular weight
21 and 35 Kd, can activate mast-cells in vitro, causing the
release of histamine, TNF-alfa, IL-3, IFN-gamma and LTB4
[72]. Differences among studies in design and diagnostic
methods make it challenging to interpret the association be-
tween H. pylori and CU. Furthermore, studies in children
are few. A systematic review concluded that the chance of
remission of CU in patients with H. pylori infection after
eradicating therapy is significantly higher than in those who
did not undergo eradication therapy or in those with CU
without H. pylori infection [70]. A slightly more recent
systematic review concluded that the evidence on benefits of
eradicating therapy for H. pylori in CU was weak and con-
flicting [73]. Moreover, in a Turkish non-comparative study,
performed on 222 children with CU, 32,8% of patients were
tested positive to C13-UBT but only in one case a complete
remission of cutaneous symptoms after eradicating therapy
was observed [56]. Similar results have been reported in
studies on smaller paediatric case series [28]. Even in adults,
studies that show that eradicating H. pylori infection leads
to the resolution or improvement of CU symptoms, are
lacking [70, 74, 75].
Concerning other bacterial infections (e.g. Streptococ-
cus, Staphylococcus, Chlamydia Pneumoniae), prevalence
in CU does not differ from that in general population.
Clinical trials either do not often clarify whether there was
resolution of symptoms after the clearance of the infective
agent [36, 58, 61, 63, 76] or they found that treatment did
not resolve the disease [56]. For example, in a Turkish
study on a large population of children, CSU resolved fol-
lowing antibiotic therapy in only one out of three patients
with positive urine culture [41].
In children with CU and parasitic infection, anti-para-
sitic agents have been sporadically reported to improve
cutaneous lesions in Western countries [77]. Blastocystis
hominis, Giardia lamblia, Dientomobea fragilis, Ascaris
lumbricoides and Strongyloides stercoralis have been fre-
quently detected [41, 56, 57, 71, 78]. The incidence of
parasitic infestations in children with CU varied from
0% to 37,8% [71]. In children, remission of CU after
anti-parasitic treatment ranged from 0 to 100% of cases
[39, 41, 56, 57, 71].
In the only study with a control group, the rate of
resolution after anti-helminthic treatment was similar in
children with and without parasitic infection [39].
Therefore, the relationship between CU and parasitic
infestation in children remains unclear. A parasitic in-
festation may be considered a potential cause of urticaria
in a few patients.
Non-controlled studies in adults have shown a high
frequency of sensitization to Anisakis in patients with
CU, with improvement of symptoms in a variable pro-
portion of patients after a seafood-free diet [79, 80]. No
data is available on the association between Anisakis
infestation and CU in children.
Viral infections (Herpesviridae, HBV and HCV) have
been identified as a cause of CU in anecdotal cases or
non-controlled studies [58, 60, 81]. A possible role of la-
tent infections by HHV-6 in adults has been suggested
[82]. Up to date, however, there is no evidence of a role
of viruses in CU in children.
• What is the role of allergy in CU in children?
Answer. There is no clear evidence that food allergens
or medications provoke CU in children (Level of
evidence V).
In children with CU, COX-1 inhibitors should not be
used unless necessary because they could aggravate
symptoms. (Level of evidence IV. Strength of
recommendation D).
There is no evidence that IgE-mediated hypersensitivity
reactions play a pathogenetic role in CU in children.
Atopy is not predictive of severity or longer duration of
CU in children [39, 41, 42, 83]. Nevertheless, a longer dur-
ation in atopic children with CIU has been reported [47].
Contact allergy
Contrasting data have been reported on the role of con-
tact hypersensitivity in CSU in adults [84–86]. Positive
patch tests for common contact allergens have been
shown in 42,9% of 543 patients, mostly adults (aged 5–
85), with differences in sensitization due to age and
occupation [86]. There is no evidence that avoidance of
aptens can improve CU.
Prevalence of atopic diseases
Adults with CU have a significantly higher prevalence of
asthma, allergic rhinitis and atopic eczema compared to
controls (10,8%, 9,8% and 19,9% vs 6,5%, 3,7% and 10,1%
respectively) [83]. Similar trials are lacking in children.
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Prevalence of atopy, defined as positive skin test or per-
sonal history of allergic diseases, ranged from 13 to
35.9% in case series of children with CU [37–42, 60].
This confirms a similar frequency in a general paediatric
population.
Total IgE levels
In adults, levels of serum IgE are related to severity and
duration of CU [87]. Higher levels of total IgE have been
reported in children with CU than in those with AU,
with no significant differences in inhaled or food aller-
gens sensitisation and circulating eosinophils [88]. The
meaning of this association is unclear.
Food allergy
Despite parents’ views [4], food allergy is a rare cause of CU
in childhood. In case series [28, 36–39, 41, 42, 56, 58, 59] of
children with CU, the prevalence of food allergy varied from
0 to 8.6%. It must be pointed out that in many studies the
oral food challenge (OFC) was not performed or, when per-
formed, it was not double-blind controlled but open. So,
reported rates are less reliable since CU is characterized by
daily symptoms. Furthermore, in children with a positive
OFC, the elimination diet did not always cure urticaria
[28, 37, 39, 41, 57, 89]. In a mixed adult and children
population, the rate of IgE mediated food allergy ascer-
tained by open OFC was 2,8% [90]. Studies in adults
but not in children show a possible correlation between
IgE to lipid transfer protein and CU [91, 92].
Aeroallergens
Although, it has been shown that aeroallergens may trig-
ger CU [59], there is no evidence of an association
between IgE mediated sensitization to inhaled allergens
and CU in children.
Medications
Medications causing CSU in children have been sparsely
reported [38, 59]. In a large population of children with
CSU, no suspected drug allergy was confirmed [41].
Regarding NSAIDs, COX-1 inhibitors, even the
ones that are not related to one-another, can exacer-
bate CU through non-immune-mediated mechanisms
[8, 92] independently from a causing role [93, 94].
In children with CSU, single blind oral challenge
with ASA was positive in 24% of cases, and lip
angioedema was the more common manifestation
[93]. CU appears also to be the main risk factor for
NSAIDs hypersensitivity in childhood [94]. There-
fore, it is advisable not to give NSAIDs to children
with CU unless necessary.
• What is the role of pseudo allergens and vasoactive
amine rich foods in children’s CU?
Answer. There is insufficient evidence that pseudo
allergens and vasoactive amine rich foods can modify
CU’s course (Level of evidence V)
Intolerance to additives has been associated to CU in
2,6 to 21% of children in low quality studies that did not
report whether a low additive diet improved symptom
[55]. In 81% (13/16) of children with idiopathic CU,
symptoms recovered after a 3-week low pseudo allergen
diet; only 6/13 patients underwent a double-blind OFC
with suspected additives, which was positive in 5/6 cases
[95]. In 100 patients with CU aged between 14 and 67
years old, two adults did not pass single blind OFCs to
11 additives including food colourings and preservatives
[96]. These two patients passed a double-blind con-
trolled OFC to the same additives. In an open study in
adults, a low pseudo allergen diet improved CSU in
around a third of the patients [97]. Limitations of the
study included lack of a control group and missing
evaluation of reintroduction of excluded foods. The
same methodological bias had an open study in adults
that showed the effectiveness of a 3–4-week low vaso-
active amine diet in 75% of patients [98]. In conclusion,
existing data do not support the causative role of pseudo
allergens in CU.
• What is the role of autoimmunity in children’s CU?
Answer. In 30-50% of children with CSU, autoimmune
mechanisms are probably implied (Level of evidence
IV). We can hypothesize the role of auto-allergens in
some forms of inducible urticaria (Level of evidence V).
In contrast to adults, the paucity of studies on
autoimmune diseases allowed to associate children’s
CU only with anti-thyroid antibodies, autoimmune
thyroiditis and coeliac disease (Level of evidence V).
CSU is often associated with autoimmune thyroiditis
and coeliac disease in children [1, 2]. Large longitudinal
studies in adults show that co-morbidity of CU and
autoimmune diseases is common [99]. There is accumu-
lative evidence that a causal relationship between type I
autoimmunity and CU is “suggestive” and between type
II autoimmunity and CU is “probable” [100].
Serum autoantibodies activating mast cells and basophils
The presence of circulating IgG autoantibodies against
high affinity receptor for IgE (FcεR1α) or anti-IgE anti-
bodies (type II autoimmunity) that can release mediators
from mast-cells and basophils is well established in
many patients with CSU [100, 101]. Functional tests
used to detect these autoantibodies include in vitro tests,
such as basophil histamine release assay (BHRA) and
basophil activation test (BAT), as well as in vivo tests,
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notably autologous serum skin test (ASST) and autolo-
gous plasma skin test (APST). In vitro and in vivo tests
are not interchangeable and study different pathogenetic
mechanisms of the disease [102, 103]. A positive ASST
has been reported in 22 to 53.5% of children with CU
[28, 37–39, 41, 58]. ASST can be positive even in healthy
subjects or in patients affected by different diseases.
Only a subgroup of patients with positive ASST has a
positive in vitro histamine releasing test [101–103]. It
has also been noted that ASST uses non-purified IgG. A
positive ASST result persists after removal of comple-
ment protein and IgG adsorption [104]. Therefore, ASST
indicates a mast cell activation induced not only by auto-
antibodies but also by other serum factors that can pro-
mote histamine release [105]. There is no difference in
the frequency of positive ASST between children with CU
affected by parasitic infestation and those without
infestation [57]. In adults with CU, APST is more fre-
quently positive than ASST [102]. There is no experience
in children about the use of APST.
Regarding in vitro tests, histamine releasing IgG anti-
FcεR1α functional antibodies have been documented in
47% of children with CU compared to 0% of controls with
atopic eczema [37]. Other studies reported significantly
higher levels of BAT in children with CSU compared to
healthy controls [106]. In these studies, there was an over-
lapping of values between the two populations, so that it
was not possible to identify a cut-off value to separate
them [42].
Autoantibodies have been detected by Western blot
method or ELISA immunoenzymatic method in adults
with CU [100], but not in children. Regarding Witebsky’s
criteria, that are necessary to define CU as a type II auto-
immune disease, direct evidence and circumstantial
evidence, drawn from clinical practice, are not complete
and an animal model is lacking [105]. Some forms of CIU
(solar, cholinergic, cold) may involve the production of
IgE against auto-allergens expressed in the skin as an
effect of thermic stress or other physical factors, as shown
by positive passive transportation test [29, 64–66].
Thyroid autoimmune disease
Patients with CU are at risk of thyroid autoimmune disease
(particularly Hashimoto thyroiditis). Case-control studies
show that in children with CSU the prevalence of auto-
immune thyroiditis is 10 to 30 times higher than in a
general population [1]. Levels of IgG anti-thyroid antibodies
are significantly increased in patients with CU compared to
controls; these levels are also higher in adults than in chil-
dren [107]. It is unclear whether anti-thyroid antibodies
play a pathogenic role. Higher anti-thyroperoxidase IgE
levels were found in adults with CSU, making it possible to
hypothesize auto-allergy mechanisms [108]. The presence
or absence of antibodies do not confirm nor exclude the
diagnosis of thyroiditis [109] and up to date a causal role of
thyroid disease on CU onset has not been proven
unequivocally [110]. In adults, thyroid diseases are often
associated with CU, while in children the prevalence of
hypothyroidism, often due to Hashimoto thyroiditis more
than Graves’ disease, is below 1% and hyperthyroidism has
not been reported [55, 107]. There is no clear evidence that
in patients with thyroid autoimmunity, CU has a different
course or that treatment with thyroid supplementation
therapy improves urticaria.
Coeliac disease
Case reports and case control studies have shown the
association between CU and coeliac disease in children
as well as adults [2, 99]. The prevalence of coeliac dis-
ease in patients with CSU varies among studies, and it is
increased by 8–10 times when compared to a general
population [2]. A remission of cutaneous symptoms after
a gluten free diet has been also reported [2]. Conversely,
studies on large populations highlighted a slightly higher
prevalence of CU as well as AU in patients with coeliac
disease in comparison to healthy controls [99, 111].
Other autoimmune diseases
Adults with CU seems to have an increased risk of develop-
ing other autoimmune diseases compared to children, pos-
sibly because incidence of autoimmune diseases rises with
age. In children with systemic lupus erythematosus, CU is
rare (0–1% of cases) when compared to adults [99, 112].
Few cases of systemic lupus erythematosus in children with
CU have been described [112]. The presence of anti-nu-
cleus and anti-DNA antibodies without connective tissue
disorders has been rarely observed in children with CU
[28, 55, 56]. The prevalence of rheumatoid arthritis,
Sjogren syndrome, type 1 diabetes is increased in adults
with CU. In childhood data are lacking [56, 99, 113].
Vitiligo, pernicious anaemia and Raynaud’s phenomenon
with anti-centromere antibodies have been sparsely re-
ported in children as well as in adults [56, 99, 113].
What is the role of the activation of coagulation and
fibrinolysis in CU in children?
Answer. Insufficient data have been reported on the
role of coagulation and fibrinolysis processes in the
pathogenesis of CU in children (Level of evidence V).
Studies on adults have shown that the coagulation
7cascade can have a role in the pathogenesis of CU. The
cascade seems to be initiated by expression of tissue fac-
tor by activated eosinophils and the release of thrombin.
In animal models, thrombin increased vascular perme-
ability with a direct action on endothelial cells as well as
an indirect one on histamine and other mediators
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released by mast-cells [103]. During urticaria exacerba-
tions, adults with CU showed increased prothrombin
fragments serum levels [1, 2, 102]. In adults with CU,
there was fibrinolysis [114, 115]. Serum levels of D-
dimer and fibrin degradation product increased during
exacerbations of CU in adults and they have been pro-
posed as markers of severity and response to antihista-
mines [115, 116]. The activation of the processes of
coagulation and fibrinolysis in CU in paediatric age is
supported by few studies on mixed adult and paediatric
populations [115] and by a Japanese study that showed
the increase of serum levels of prothrombin fragments 1
and 2 in the small group of children with CU [117].
Question 6. Is CU in children associated to other
organ diseases or systemic diseases more frequently
than in non-selected population?
Answer. There is no evidence of an association of CU
in children and other organ or systemic diseases (Level
of evidence V)
Although in adults it has been reported that CU is asso-
ciated with rheumatic, inflammatory and psychiatric
diseases [118], irritable bowel disease [119], cancer [120]
and metabolic syndrome [121], the evidence is insuffi-
cient. There are no similar studies on children. Consti-
pation and irritable bowel are not more frequent in
children with CU [122].Question 7. Can psychological
factors determine CU or exacerbate it?
Answer. Studies performed on adults might suggest a
role of psychological factors in the development or
exacerbation of CU. In small populations of children,
weak data seem to support this hypothesis (Level of
evidence IV).
Many studies suggested that psychological factors might
contribute to the development or the exacerbation of
CU, supposing that they could play a role in its patho-
genesis. Some authors suggested an interaction between
nervous and immune systems [123]. Animal models have
pointed out that acute stress caused the activation of
skin mast-cells and the expression of corticotrophin re-
leasing hormone receptors [124]. Adults with CU had
significantly higher scores in tests to diagnose obsessive-
compulsive disorders, depression, anxiety, insomnia,
stressing events than controls [123]. In adults, numerous
studies have been performed [6, 123, 125], but in chil-
dren data are still few. In 27 children with CU, there was
a higher prevalence of psychiatric disorders (70% vs
30%), mainly anxiety and depression, but also separation
anxiety, specific phobias, psychosomatic disorders than
in controls [126]. No correlation has been found with
severity or duration of disease. About 2/3 of children
underwent a stressing event in the 6 months before the
onset of CU. More trials are needed to clarify the role of
psychological factors in causing or aggravating CU, and
the efficacy of a multidisciplinary approach with appro-
priate psychological and pharmacological support.
Question 8: Can clothes or temperature changes
worsen CU?
Answer. There are no studies that document the role of
clothes and temperature on the course of CU in
children, excluding subjects with cold-urticaria, heat-
urticaria, cholinergic urticaria (Level of evidence VI).
Diagnostic work-up
The aim of the diagnostic work-up is to establish criteria
to recognize patients with urticaria, make a differential
diagnosis, identify triggering factors, assess disease activ-
ity and its control.
Question 9. Which are the criteria that allow to
diagnose CU in children?
Recommendation. The diagnosis of childhood CU is
based on appearance of itchy wheals, not always
associated with AE, persisting daily or on most days
for at least 6 weeks. No laboratory test is needed to
diagnose CU (Level of evidence VI. Strength of the
recommendation A)
The diagnosis of CU is based on history and occurrence
and duration of wheals, typically itchy, migrating, fading
with finger pressure. The duration of a single lesion is
usually less than 24 h with episodes lasting over 6 weeks.
AE is characterized by non-erythematous oedema, associ-
ated to a burning or pain sensation lasting up to 72 h,
often located in the face, genitalia and extremities. There
is no instrumental or laboratory test to diagnose CU.
Question 10. Which conditions should be considered in
the differential diagnosis of CU and what are the
clinical or laboratory criteria that help in the
differential diagnosis? Are vasculitic urticaria,
monogenic syndrome associated urticaria and
bradykinin mediated AE different clinical entities from
common CU?
Recommendation. Differential diagnosis is necessary in
any case of CU as wheals can be found in many
acquired or hereditary conditions, with different
pathogenic mechanisms, such as papular urticaria,
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mastocytosis, some vasculitis and genetic syndromes.
Wheals must also be differentiated from other
elementary lesions, as papulae. Recurrent isolated AE
should be distinguished from bradykinin mediated
angioedema, hypoproteinemic oedema and some
cancers. An evaluation of morphology of lesions,
duration and associated signs and symptoms leads
toward a diagnostic hypothesis that must be confirmed
or not by diagnostic tests listed in Table 2 (Level of
evidence VI. Strength of recommendation A).
CU should be distinguished from many genetic or ac-
quired diseases, based on various clinical characteristics
and the result of diagnostic tests [127–135] (Table 2). Vas-
culitic urticaria and monogenic syndrome associated urti-
caria can be differentiated from common CU because of
their different macroscopic appearance, histology, clinical
evolution of lesions and response to therapy.
Question 11. What is the role of history and physical
examination in identifying the aetiology of CU in
children?
Recommendation. History and physical examination
are the guide to identify a possible underlying cause of
CU and decide whether other diagnostic tests are
needed (Level of evidence V. Strength of
recommendation A).
History is the first step in the diagnostic process of CU
[6, 8, 25, 55]. Clinical history is helpful to differentiate
CSU from CIU and to identify a specific cause [25, 56].
Clinicians should investigate:
 Frequency and duration of skin lesions. Wheals
lasting over 24 h lead to delayed pressure related CU
or vasculitic urticaria. On the contrary, wheals
lasting less than an hour are common in physical
urticaria (except for pressure induced urticaria).
 Shape, dimension, distribution of wheals.
 Presence of isolated or associated angioedema.
 Family history of atopy, urticaria, systemic disorders.
 Age at onset of symptoms.
 Triggering and aggravating factors, particularly food
habits, medications, physical exercise or physical
factors, supposed interval between exposure a wheal
appearance.
 Circumstances and places when symptoms occur
(night/day, inside/outside, free time...).
 Systemic signs and symptoms that suggest organ or
systemic diseases, such as coeliac disease, vasculitic
urticaria or auto-inflammatory conditions such as
periodic cryopyrin-associated syndromes [134, 136, 137].
 Subjective symptoms, as pain, burn, itch.
 Quality of life.
 Former tests executed.
 Effectiveness of present or past treatment.
Any laboratory test should be performed when history
and clinical data suggest an eliciting factor or a systemic
disease to confirm its role in the pathogenesis [138, 139].
Question 12. In case of suspected CIU, is it necessary
to perform diagnostic tests for inducible urticaria?
Recommendation. Specific tests should be used to
confirm the suspect of inducible CU (Level of evidence
V. Strength of recommendation B).
Specific tests (Table 3) should be performed to con-
firm the suspicion of inducible urticaria and when pos-
sible, to determine minimal stimulation cut-off, useful to
define the activity of disease and response to therapy
[7, 25, 140, 141]. It must be underlined, however, that
in 1/3 of cases tests result negative. Different types of
inducible urticaria can co-exist in the same subject; in
this case the various triggers should be tested in sequence
[142, 143]. To make the tests more reliable, anti-hista-
mines and corticosteroids should be interrupted 3 and 7
days before the test respectively. Stimuli should be applied
to parts of the body that were not involved by urticaria in
the last 24 h, to avoid a reduced response due to tempor-
ary local refractoriness.
Question 13. When clinical history does not indicate
an underlying cause, is it recommended to perform
laboratory tests to identify allergic or infective triggers,
in a child?
Recommendation. When clinical history does not
suggest a temporal relationship between exposure to
an allergen and onset of symptoms, it is not
recommended to perform allergy tests to foods,
additives, inhaled particles or medications (Level of
evidence VI. Strength of recommendation D).
When there is a history of cause-effect relationship
between exposure to an allergen and occurrence of
urticaria and IgE tests are positive to the relevant
allergen, diagnosis can be ascertained by effectiveness
of allergen avoidance and positive provocation test to
the same allergen (Level of evidence V. Strength of
recommendation A).
Diagnostic tests for infectious disease should be
performed only when there is a suspicion based on
clinical history or laboratory tests (Level of evidence V.
Strength of recommendation B).
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Table 2 Differential diagnosis of chronic urticaria
Disease Clinical criteria Laboratory/instrumental data Diagnostic criteria
Mastocytosis [127–129] -Maculae, round or oval papulae, brownish,
from few mm to 2 cm diameter. Lesions
become erythematous and swollen after
mechanical stimulation (Darier’s sign).
-Asymptomatic, rarely mild itch.
-Systemic forms are associated with flushing,
wheezing, abdominal pain, diarrhoea, syncope.
-Possible elevated serum tryptase in
intercritical phase (systemic
mastocytosis).











papulous dermatitis) [130, 131]
-Erythematous papulae of few mm diameter
on exposed areas (face, limbs), isolated or
confluent, sometimes with vesicles on top,
rarely itchy. Long persistence. Spontaneous
resolution. [128]




Vasculitic urticaria [132, 133]
Normocomplementemic
-Papulous erythemato-purpuric lesions that
do not fade with finger pressure, lasting over
24 h. Pain and/or burning feeling, sometimes
itch. It can be associated with fever, arthralgia,
petechiae. Lesions resolve with secondary
hyperpigmentation.
-Blood cell count.
-Increase of inflammatory markers,
ANA, anti-DNAds antibody, rheumatoid
factor positivity.








-Association with systemic lupus
erythematosus.
- Hypocomplementemia (C1q, C3, C4).
-Elevated ESR.








Mc Duffie syndrome with
anti-C1q antibodies
-Urticaria for over 6 months associated with
arthritis, arthralgia, lung pathology, uveitis,
episcleritis, glomerulonephritis.
-C1q, C3, C4; anti-C1q autoantibodies. -History.















(NOMID) or chronic infantile
neuro-cutaneous articular
syndrome (CINCA)
-Autosomic dominant, de novo mutations
described.
-Early onset in the first months of life.
-Plaques, erythema or papulae that disappear
in 24 h; no itch.
-Exanthema, fever, arthralgia and conjunctivitis
after 1–2 h of exposure to cold, lasting < 24 h.
-Arthralgia or periodic arthritis, conjunctivitis,
secondary generalized amyloidosis, neurosensory
deafness.
-Maculo-papular wheal-like eruption, non-constant
fever, failure to thrive, neurosensory progressive
hypoacusis, uveitis, optic neuritis to blindness,
variable articular symptoms, non-foreseeable
defects of long bone growth, chronic meningitis,
chronic headache, intellectual disability.
-Increased ESR, CRP, anaemia,
neutrophilic leucocytosis, absence of
autoantibodies.
-Negative response to cold challenge.


















Tumor necrosis factor (TNF)
receptor 1 associated periodic
syndrome (TRAPS)
-Neutrophilic leucocytosis, increased







-Dominant autosomic or de novo mutation.
-Isolated angioedema lasting more than 24 h;
no itch; sometimes gastrointestinal or respiratory
involvement.
-No response to anti-histamines.
-Two different types, a most frequent one
caused by C1-INH quantitative defect, the
other by functional impairment.
-Decrease of C4 levels.
-Reduced C1-INH in the first type.
-C1-INH and C4 levels reach adult levels
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An IgE mediated reaction to foods or medications can
be considered a potential cause of CU when the reaction
develops within one or two hours following allergen ex-
posure and it vanishes in a few hours. Regarding allergic
reaction to NSAIDs, they can occur within 24 h. If the
interval time between allergen exposure and urticaria oc-
currence is different, IgE mediated reactions are ruled
out and allergy tests (skin prick test [144], serum specific
IgE, challenge) to foods [145] and medications [146]
should not be performed. Patch tests to foods are not rec-
ommended [147].
Additives, preservatives and colouring free diet in foods
and medications should be advised only in the rare cases
in which we can suspect a relationship between their in-
take and the onset of symptoms. If the diet is effective, a
double-blind placebo-controlled provocation test is
needed to firmly establish the diagnosis.
The rate of resolution of CU after the eradication of
infectious agent is low [4, 8, 25, 41, 55, 56, 71, 78, 96].
Therefore, viral, bacterial and parasitic infections must
be investigated only in patients with suggestive history
or laboratory tests. There is weak evidence that labora-
tory testing for parasites should be performed in patients
with history of abdominal pain [56, 78], earlier infesta-
tions, staying in regions at risk, unexplained eosinophilia
[71]. In patients with CU a parasitic infestation is not
associated with AE, total IgE levels, high CRP, positive
prick test, positive ASST [56].
Question 14. Is it useful to perform Autologous
Serum Skin Test (ASST) in the diagnostic workup of
CU?
Recommendation. ASST should be considered a
screening test for autoantibodies (Level of evidence
IV. Strength of recommendation B). ASST should not
be routinely performed in children with CU (Level of
evidence IV. Strength of recommendation D)
Table 2 Differential diagnosis of chronic urticaria (Continued)
Disease Clinical criteria Laboratory/instrumental data Diagnostic criteria
Hypoproteinemic oedema -Peripheral swelling, serous cavities effusion.







Head and neck tumors,
lymphoma





Table 3 Diagnostic tests for CIU [7, 25, 140, 141]
Type of urticaria Site Test Time to read results
Dermographism Volar surface of the forearm or
superior surface of the back
Rub with a blunt smooth object
(pen, dermatographometer, 36 g/mm2)
10 min
Cold urticaria Volar surface of the forearm Ice cube in a plastic or a thin film
for 5 min; TempTest®
10 min
Heat urticaria Volar surface of the forearm Heat source at 45 °C (es: TempTest®,




Back or thigh or volar surface
of the forearm
Weight over arm or shoulder (7 kg
backpack) for 15 min. Dermographometer
100 g/mm2 for 70 s in research
6 h (0.5–12 h)






Volar surface of the forearm Vortex for 5 min at 1000 rpm 10min
Cholinergic
urticaria
1. Exercise test (free run or tapis roulant
or cyclette) for 15–30min.
2. Immersion of body or arm in water at
42 °C for ≥15 min after increasing body
temperature≥ 1 °C higher than basal
temperature
During the tests and
10 min after the end
Aquagenic
urticaria
Trunk Compress with 35–37 °C water for 20–30 min At the end of the test
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Functioning circulating IgG antibodies against high affin-
ity receptor of IgE (Fc (epsilon) RI (alfa) receptor), and
against IgE themselves, can be measured in vitro by BHRA
or by BAT, which are both poorly standardized methods. It
is also possible to use Western Blot or ELISA, non-com-
mercialized immunoassay, which are expensive, have little
specificity and sensitivity and do not differentiate between
functional and non-functional autoantibodies [148, 149]. In
vivo, ASST showed lower diagnostic accuracy when com-
pared to BHRA [37] since it contains both IgG and serum
factors that can promote histamine release. Therefore, the
test must be considered an expression of auto-reactivity,
and not of the presence of functional autoantibodies.
Negative ASST excludes an autoimmune pathogenesis
even in patients with positive BHRA or BAT. In chil-
dren, there is a concordance of 83% between ASST and
BHRA [37, 58]. None of the proposed tests allows to for-
mulate a certain diagnosis of autoimmune CU and it has
been proposed as diagnostic gold standard the presence
of a positive biological test (BHRA, BAT with CD63 ex-
pression), of ASST and of an enzymatic immunoassay
[105]. From a clinical point of view, in children with CU,
there are contrasting data on the association of positive
ASST and CU severity [150, 151], time course [39] or re-
sponse to treatment. In adults, it is unclear whether
ASST negativization occurs when CU resolves [152–
155]. Therefore, ASST should not be routinely per-
formed. In BAT, high levels of expression of CD63 are
associated with a higher urticaria activity score 7
(UAS7), although with low sensitivity and specificity
[106].
Question 15. Is it useful to perform tests to rule out
coeliac disease, thyroiditis, other autoimmune or
neoplastic disorders in children with negative history
and physical examination?
Recommendation. Children with CU should be
screened for coeliac disease and thyroid diseases (Level
of evidence V. Strength of recommendation B) but not
for other autoimmune diseases or malignancies (Level
of evidence V. Strength of recommendation D).
CU in children is rarely associated with hypothyroidism
[55, 107, 109, 110], anti-thyroid antibodies [1, 112], or
coeliac disease [111]. Coeliac disease can cause CU2. La-
boratory tests to identify these conditions should be ob-
tained in all patients, even when specific symptoms are
lacking [99]. It has also been advised to monitor patients
with CU because they can develop hypothyroidism or
anti-thyroid antibodies [8] over time.
In childhood, it is not adviseable to investigate auto-
immune diseases or cancers, since case reports have
been hardly reported [28, 55, 56, 112, 113].
Question 16. Which diagnostic workup is appropriate
for children with CSU?
Recommendation. In children with CSU with negative
history and physical examination, it could be
considered to perform blood tests for inflammatory
diseases (blood cell count, CRP, ESR (Level of
evidence V. Strength of recommendation B), and to
test for autoimmune diseases (coeliac disease,
thyroiditis) (Level of evidence V. Strength of
recommendation B.)
In the diagnostic workup of CSU (with or without
AE), history and physical examination are the basis to
establish the need to perform laboratory tests and to
choose their sequence. If history and physical examin-
ation are negative, laboratory tests are rarely useful
[138, 139, 156]. Diagnostic testing for autoimmune
diseases, associated to CU, can be performed.
This task force proposes, therefore, a simple diagnostic
workup (Fig. 1).
1. If a single wheal lasts over 24 h, and delayed pressure
urticaria is ruled out, a skin biopsy can be necessary to
confirm a diagnosis of vasculitic urticaria.
2. If a single wheal lasts less than 24 h, different
possibilities must be considered.
a) If history or clinical features are suggestive for
underlying causes (physical factors, medications, foods,
additives, infections, autoimmune diseases) specific
diagnostic tests should be performed. Dermographism,
however, should be searched in all children with CU.
b) In case of recurrent, isolate AE, without any clinical
feature or history of associated diseases, hereditary AE
should be ruled out [157].
c) When there is a suspicion of a genetic disorder,
cryopyrin gene should be analysed.
d) In the remaining cases, children might undergo
additional tests including blood cell count, ESR, CRP to
reassure parents on the benignity of the clinical condition;
FT4, TSH, anti-microsome antibodies, anti-thyroglobulin
and anti-thyroperoxidase antibodies, DGP-AGA (under 2
years of age), anti-TTG, IgA to identify the association
with autoimmune diseases.
e) ASST and BAT should not routinely be performed
to better understand the pathogenesis or for research
purposes.
Question 17. Is it advisable to use severity scores in
children with CSU?
Recommendation. Currently there are no validated
severity scores for CSU in paediatric age. However, in
clinical practice it is possible to use adult scores
(Urticaria Activity Score 7-UAS 7) to rate the severity
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of disease and to assess the response to treatment
(Level of evidence V. Strength of recommendation B).
The severity of CU should be evaluated in daily prac-
tice as well as in clinical trials. Currently there is no se-
verity score that is validated for CU in children.
Urticaria Activity Score (UAS7) [7] is the most used
score to determine disease activity, its impact on quality
of life and response to therapy. Some authors proposed
its use in the child [42], even adapting it to body sur-
face [158]. UAS7 is the sum of daily symptoms’ scores
during a period of 7 consecutive days. It is requested to
the patient to fill a sheet where he daily records the se-
verity of itch and the number of wheals for 7 days [7].
UAS7 allows then to categorise the severity of CSU in
severe (28–42), moderate (16–27), mild (7–15), well
controlled (1–6), absent (0), and to define response to
treatment (Table 4). UAS7 should be checked at fol-
low-up visits.
UAS7 has some weaknesses. It is based on self-evaluation
only; being a prospective score, it cannot be used during
the first evaluation of the patient; its evaluation is difficult
if the patient forgets to mark the score on some of the
days. Other scores have been validated in adults: Angio-
edema Activity Score to evaluate AE [159], Urticarial Con-
trol Test to evaluate the control of the disease [160, 161].
Treatment
The first goal of treatment of urticaria is to control
symptoms by avoidance of the triggering factor. When
this is not possible, the approach to treatment of CU re-
quires a symptomatic medication.
Question 18. Can treatment of autoimmune thyroiditis
or coeliac disease cure CU?
Recommendation. There is no clear evidence that
treatment of autoimmune thyroid disease or coeliac
Fig. 1 Algorithm for diagnosis of subtypes of CU
Table 4 Weekly Urticaria Activity Score (UAS 7) [7, 158]
DAY SCORE WHEALS/24H SCORE ITCH/24H SUM
None < 20 20–50 > 50 Absent Mild Moderate Intense
1 0 1 2 3 0 1 2 3 … ..
2 0 1 2 3 0 1 2 3 … ..
3 0 1 2 3 0 1 2 3 … ..
4 0 1 2 3 0 1 2 3 … ..
5 0 1 2 3 0 1 2 3 … ..
6 0 1 2 3 0 1 2 3 … ..
7 0 1 2 3 0 1 2 3 … ..
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disease associated with CU can have an impact on
natural course of CU. However, in clinical practice the
treatment is advisable (Level of evidence V. Strength of
recommendation B).
(Level of evidence V).
The hormone replacement therapy, used in patients
with hypothyroidism, can positively affect CU [107].
In case of euthyroidism, even in presence of anti-thy-
roid antibodies, the treatment with L-Tiroxine is not
advised [6], and thyroid monitoring should be contin-
ued. The resolution of CU during a gluten free diet
has been sporadically observed in patients with
coeliac disease [2].
Question 19. Is it advisable to start an additive and/or
pseudo allergen free diet in the child with CU?
Recommendation. When history is negative, children
should not go on an additive and/or pseudo allergen
free diet (Level of evidence V. Strength of
recommendation E).
Studies [55] on the efficacy of a pseudo allergen free
diet, including additives and preservatives, in CU are few
and performed on mixed case series of adults and chil-
dren. These studies did not provide evidence that these
interventions are effective when history is negative.
Question 20. What is the drug of choice for CU?
Recommendation. Second-generation H1-
antihistamines are the first-choice treatment for CU
(Level of evidence I. Strength of recommendation B).
Second (new)-generation H1-antihistamine are the first
option in the treatment of CSU. A recent review of 73
studies with 9759 participants, including adolescents
over 12 years of age, although none of them included
specific paediatric data, concluded that anti-H1 anti-his-
tamine drugs are beneficial in less than 50% of cases
[162]. More recently, a blind randomized controlled trial,
performed on mixed adult and adolescent populations,
confirmed the efficacy of cetirizine (10 mg), fexofenadine
(180 mg), bilastine (20 mg), desloratadine (5 mg), ebas-
tine (20 mg) [163]. In a non-controlled prospective study
in subjects with AU or CU aged 11 to 92 years, levocetir-
izine 5 mg daily for 2–6 weeks greatly improved or re-
solved symptoms in 60–80% of patients. Overall, 50–
74% of patients perceived improvements in quality of
sleep/daily activities and 50–65% of patients rated the
onset of action for levocetirizine as very rapid or rapid
[164]. In a comparative double-blind placebo-controlled
trial [158], in subjects aged 2–11 years old, no significant
difference has been found between desloratadine and
rupatadine in wheal reduction. However, rupatadine, but
not desloratadine, reduced the itch significantly com-
pared to placebo. Quality of life was significantly better
in patients treated both with rupatadine and with deslor-
atadine. No difference was found in incidence of adverse
effects between active groups and placebo group.
Second generation H1 antagonists are generally well
tolerated [158, 162, 163, 165–168], except for astemi-
zole and terfenadine whose metabolism by P450 liver
cytochrome can be blocked by the concomitant ad-
ministration of ketoconazole or erythromycin, causing
cardiotoxic effects.
H1-antihistamines should be given for 1–2 weeks and,
if effective, the need to continue should be re-evaluated
every 3–6 months. Second generation H1 antagonists,
approved for paediatric use, are listed in Table 5. Levo-
cetirizine, active enantiomer of cetirizine, has been ap-
proved by FDA to treat non-complicated CSU in
children from 6months of age [166]. Earlier long-term
studies have shown a good safety and tolerability profile
of cetirizine and levocetirizine administered at a double
dose in children aged between 12 and 24 months old,
suffering from atopic dermatitis [169, 170]. Bilastine has
a good tolerability and safety profile in children aged 2
to 12 years old suffering from CU [167]. It is desirable to
have more clinical trials that can make the data applic-
able to the whole paediatric population and that can be
transposed into law by the drug regulation authorities.
The use of first-generation H1-antihistamines (es.
hydroxyzine) is not recommended [165, 171, 172].
They are poorly selective against H1 receptor and can
easily cross the blood-brain barrier. Consequently,
they more frequently determine adverse event than
second-generation antihistamines, including sedation,
dry mouth, headache, blurred vision, glaucoma, urin-
ary retention [162].
Question 21. Is there any evidence of greater efficacy of
a H1-antihistamine compared to the others? In case of
failure of H1-antihistamine at standard dosing, should
a different H1-antihistamine be used?
Answer: There is no evidence that any H1-
antihistamine is more effective than the others in the
treatment of CU, therefore no specific H1-
antihistamine is recommended as a first option. (Level
of evidence I. Strength of recommendation D.)
The efficacy of the available H1-antihistamines at stand-
ard doses has been evaluated in a recent systematic
review [162]. Desloratadine exhibited superior efficacy
than placebo in inducing complete remission in
Caffarelli et al. Italian Journal of Pediatrics          (2019) 45:101 Page 14 of 25
medium-term (5mg q.d./2 weeks-3 months) and short-
term (20 mg q.d./2 weeks) therapies, although no differ-
ence was observed between 5mg q.d. and 10mg q.d. or
short-term treatments. Comparisons between loratadine
(10 mg q.d.) vs placebo and vs cetirizine (10 mg q.d.) in
short- and medium-term therapies did not show signifi-
cant differences in terms of “good or excellent response”
or complete remission of CU. No significant differences
were found between loratadine (10 mg q.d.) vs deslorata-
dine (5 mg q.d.) in medium-term therapy efficacy. Lora-
tadine (10 mg q.d.) and hydroxyzine (25 mg q.d.) were
found to be effective and comparable to each other in
inducing complete remission in short-term treatments.
There was no difference between loratadine (10 mg q.d.)
and mizolastine (10 mg q.d.) in terms of complete remis-
sion of symptoms and improvement of the quality of life
≥50% [162]. Levocetirizine was effective at a dose of 5
mg/day in medium-term therapies, but not in short-term
ones, while a higher dose (20 mg q.d.) proved to be ef-
fective in short-term therapy. In comparative studies,
levocetirizine (5–20mg q.d.) was more effective than
desloratadine (5–20 mg q.d.) [162]. Cetirizine has been
shown to determine the remission of CU in more
patients then fexofenadine [162]. The authors [162]
concluded that none of second generation H1-antihista-
mines was more effective than the others in the control
of CU symptoms, although the quality of evidence was
heterogeneous.
Adverse events of H1-antihistamine have some inter-
individual variability, some subjects “tolerate” an
antihistamine better than another [162, 173]. In a pla-
cebo-controlled comparative study, there were no sig-
nificant differences in drug withdrawal rates due to
adverse events between the active group (cetirizine 10
mg q.d. and 20mg q.d., desloratadine 5 mg q.d., hy-
droxyzine 25 mg q.d.) and placebo [162].
Rupatadine at standard doses (10 mg q.d.) has a good
tolerability and safety profile in children aged 2–11 years.
In a double-blind, randomized, placebo-controlled study
carried out in children aged 2–11 years with CSU, no
significant differences were found in reducing wheals be-
tween desloratadine and rupatadine, although rupatadine
but not desloratadine was statistically superior to pla-
cebo in reduction of pruritus (− 57%). Children’s quality
of life was statistically improved both in subjects treated
with rupatadine and with desloratadine compared to
Table 5 Second-generation anti-H1 anti-histamine for children
Second-generation
H1-antihistamines
Pharmaceutical form Age and/or weight Dose
Cetirizine Drops 10 mg/ml
(1 drop = 0,5 mg)
Oral solution 1 mg/ml
Tablets 10 mg
2–6 years 2.5 mg b.i.d.
6–12 years 5 mg b.i.d.
12–18 years 10 mg q.d.
Loratadine Syrup 1mg/ml
Tablets 10 mg
2–12 years (< 30 kg) 5 mg q.d.
2–12 years (> 30 kg) 10 mg q.d.
12–18 years 10 mg q.d.
Fexofenadine Tablets 120 mg
Tablets 180 mg
(Tablets/syrup 30mg in US/UK)
12–18 years
(US> 2 years, UK > 6 years)
120–180mg q.d.
30 mg q.d.
Levocetirizine Drops 5 mg/ml
(1 drop = 0,25 mg)
Tablets 5 mg
2–6 years
(in US > 6months)
1.25 mg q.d.
> 6 years 5 mg q.d.
Desloratadine Oral solution 0,5 mg/ml
Tablets 2.5 mg
Tablets 5 mg
1–5 years 1.25 mg q.d.
6–11 years 2.5 mg q.d.
> 12 years 5 mg q.d.
Acrivastine Syrup 8mg/10ml
Tablets 8 mg
> 12 years 8 mg t.i.d.
Rupatadine Oral solution 1 mg/ml
Tablets 10 mg
2–11 years (< 25 kg) 2.5 mg q.d.
2–11 years (> 25 Kg) 5 mg q.d.
> 12 years old 10 mg q.d.
Bilastine Syrup 2.5 mg/ml
Tablets 10 mg
Tablets 20 mg
> 6 years (> 20 kg) 10 mg q.d.
> 12 years 20 mg q.d.




(> 2 aa in Europe)
10–20 mg q.d.
(0.2 mg/kg q.d.)
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placebo. The incidence of adverse events was equal to
placebo in both active groups [158].
In a prospective, open, randomized study [168] in 100
patients aged 12–65 years old, levocetirizine was found
to be more effective than rupatadine in CU patients, but
both drugs caused mild sedation.
Question 22. In case of failure of second-generation
H1-antihistamine at standard dosing, what are the
options? Should the dosage of H1-antistamines be
increased? If there is no control of symptoms, should a
different H1-antihistamine be prescribed?
Recommendation. In children over 12 years of age, if
standard dosing of second-generation H1-
antihistamine does not adequately control CU, after
evaluation of the risk-benefit ratio, an increase in the
daily dosage (by increasing frequency of administration)
up to fourfold may be recommended (off-label) (Level of
evidence I. Strength of recommendation B)
In children <12 years, although no study is available,
increasing the dosage can be evaluated, considering
that doubling daily doses of second-generation H1-
antihistamines has been proved safe in large controlled
studies (Level of Evidence I. Strength of Recommendation
C). Although there is no evidence of relevant clinical
difference among new H1 antagonists, in patients who do
not respond, a course of treatment with a different
molecule can be tried. (Level of Evidence VI. Strength of
Recommendation C).
Some authors have described the benefit of a higher
dosage (up to fourfold) of second generation H1-anti-
histamines, in order to control symptoms without com-
promising the safety profile of these drugs [162, 174].
This approach is recommended by European guide-
lines [7] based on the assessment of the risk-benefit
ratio [175] The efficacy of this approach has been
shown in randomized controlled studies on adoles-
cents aged> 12 years old and adults using up to four-
fold higher dosage than standard one of cetirizine,
fexofenadine, bilastine, ebastine, desloratadine in CU
[163, 176] and desloratadine, rupatadine and bilastine
in cold-induced urticaria [177, 178]., without signifi-
cant increasing in side effects. Other studies have
observed the efficacy of H1-antistamines at increased
dosage [179–183]. The evidence about the use of H1-
antihistamines at increased dosage over long term is
not yet available.
Question 23. When second-generation H1-
antihistamines are not adequate to control CU, should
a combination of second-generation H1-antistamine
and first-generation H1-antihistamine or H2-
antihistamine be given?
Recommendation. A combination of second-generation
H1-antistamine and first-generation H1-
antihistamine, or of H1-and H2-antagonists should
not be given in CU. (Level of evidence I. Strength of
recommendation D).
Few studies have evaluated the combined use of differ-
ent anti-H1 antihistamines at standard or increased
dosage. A systematic review concludes that there is no
evidence for recommending this option, although it is
sometimes used in clinical practice [162]. In adults with
CU, adding a first-generation H1-antihistamine (hy-
droxyzine) to a second generation H1-antihistamine
(levocetirizine) is not more effective than levocetirizine
alone [184]. A systematic review, including studies in
adults, pointed out that the evidence about the efficacy
of H2-antagonists for the treatment of CU is weak and
unreliable [185].
Question 24. When second-generation H1-
antihistamine do not adequately control CU, could
other treatments be recommended in children?
Several treatments have been proposed for use as sec-
ond and third line therapy in antihistamines-refractory
patients. In children, clinical trials on these therapies
are lacking or of low quality, except for omalizumab.
Therefore, the strength of recommendation is weak,
except for omalizumab because of little or no evidence
of efficacy, high costs and frequent poor tolerability.
When these treatments are started, antihistamines and
other drugs that were helpful to the patient should be
continued (Fig. 2).
Omalizumab
Recommendation. In patients 12 years of age and
older with CSU, omalizumab should be added to
second-generation H1-antistamines as a second-line
therapy when second-generation H1-antistamines
alone do not give adequate relief. (Level of evidence I.
Strength of recommendation A) (Figure 2)
Omalizumab, a monoclonal antibody against IgE, is
approved for the treatment of children with CSU 12
years of age and older when CSU is not controlled
by H1-antihistamine. Studies on omalizumab for the
treatment of CSU were mainly performed on adult
subjects, and in some cases, paediatric patients (> 12
years old) were also included. Omalizumab achieved
statically significant reduction of clinical score and it
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was safe. Three randomized controlled trials [186–188]
including paediatric patients are available. Ninety pa-
tients (5 aged < 18 years) with UAS7 > 12 where ana-
lysed in a prospective, randomized, quadruple-blind,
placebo-controlled, dose-ranging study. They were
randomized to receive placebo or omalizumab every
4 weeks in 3 different dose injections (75 mg, 300 mg,
600 mg). Both the 300-mg omalizumab group and the
600-mg omalizumab group showed greater improve-
ment than the placebo group in UAS7 (13.0 e 7.7
points respectively) [186]. The multicentre phase III
ASTERIA II study, randomly assigned 323 patients
(10 aged < 18 years) with CSU resistant to standard
H1-antihistamine therapy and UAS7 > = 16 to receive
omalizumab at doses of 75 mg, 150 mg, or 300 mg or
placebo, during a period of 12 weeks. The authors
found a significant reduction in the average itch-se-
verity-scores (ISS) in the group receiving doses of 150
and 300 mg (primary efficacy outcome), and also a re-
duction in UAS7, number of lesions, DLQI (Derma-
tology Life Quality Index), number of patients with
UAS7 < 6 and proportion of patients with MID (min-
imally important difference) response in weekly itch-
severity scores at 12 weeks (secondary outcome). Ad-
verse events observed showed no significant differ-
ences in the different groups, although the rate was
higher in the group treated with 300 mg [187]. The
multicentre phase III ASTERIA I trial, a randomized,
double-blind, placebo-controlled study, evaluated the
efficacy and safety of omalizumab in 319 patients (18
of whom < 18 years). Patients were randomized to
receive omalizumab 75 mg, 150 mg, or 300 mg or pla-
cebo for 24 weeks. The treatment groups (75 mg, 150
mg and 300 mg) had significant improvement in sec-
ondary outcomes and maintenance of efficacy at 24
weeks compared to placebo, without significant ad-
verse events [188]. The three trials [186–188] had a
low risk of bias in randomization, masking, blindness,
dropouts during treatment or follow-up, coherence in
reporting. Potential biases were represented by the
sponsorship of the studies and by the limited number
of paediatric patients.
Two other randomized trials have shown the efficacy
and safety of omalizumab in adult patients [189, 190].
The response was often observed within a week after the
first dose and there are slow responders after 3–5
months. Patients usually relapse after a few months
when omalizumab is stopped.
A prospective open-label (real-life) study evaluated the
efficacy of 150mg of omalizumab, at intervals ranging
from 15 days to 7 weeks, in 68 patients with severe re-
fractory urticaria. 78% achieved complete remission dur-
ing omalizumab therapy (UAS-7 0) [191]. Another study
treated 47 CU patients aged from 16 to 74 years with
Omalizumab at a dose of 150 mg/month or 300mg/
month. 84% of patients treated with the highest dose
achieved clinical remission. Of the 20 patients who
started the treatment with 150mg of omalizumab, 12
(60%) had a complete response. In 6 of the partial re-
sponders, a higher dose of 300 mg was used: 4 of them
(66.7%) had a complete resolution of symptoms with
300 mg but 2 still have symptoms [192].
Fig. 2 Treatment of CU in children. *off-label
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Despite the lack of studies in children, the trials pub-
lished up to date showed efficacy and tolerability of omali-
zumab. The small number of adolescents who were
enrolled in the phase 3 trials [186–188] is a limitation.
Whether the baseline clinical findings reported [186–188]
can be generalized for this patient population is unknown.
This, in combination with the small number of real-world
studies, highlights the need for larger studies focusing on
efficacy of omalizumab in the subgroup of adolescents
with CSU. Case reports of efficacy of omalizumab in chil-
dren less than 12 years of age have been reported [193,
194]. A limitation of omalizumab is the cost that may be
unaffordable in many circumstances. Regarding CIU, there
are sparse reports of efficacy of omalizumab in children
with cold urticaria [195–197] and solar urticaria [198].
Cyclosporin-A
Recommendation. The use of ciclosporin-A can be
considered when the combination of second-generation
H1-antistamines and omalizumab is not enough to
control CSU or patients have not access to omalizumab.
Its use is limited by possible side effects (Level of
evidence V. Strength of recommendation C).
The efficacy of cyclosporin A has been shown in some
children with CSU, that was not controlled by high-dose
antihistamine [199] or the combination of antihistamine
and prednisone [200].
In a prospective, open-label study in 30 patients aged
over 18 years, a 5-month cyclosporin-A course has
shown good efficacy, 87% of patients was symptom-free
after one year of follow-up but there was also a signifi-
cant number (7/30) of dropouts due to adverse events
and failure of low-dose therapy [201]. In adults, cyclo-
sporine A is less effective than omalizumab [202].
Prescription of Ciclosporin A is off-label.
Systemic corticosteroids
Recommendation. A short course (up to 10 days) of
systemic glucocorticoids can be used during severe CU
exacerbations. (Level of evidence VI. Strength of
recommendation B.)
Long-term treatment with systemic glucocorticoids
should be avoided because of the risk of significant side
effects (Level of evidence VI: Strength of
recommendation E).
Oral corticosteroids should be used as a rescue therapy in
severe CU exacerbations. There are no controlled studies
on the use of corticosteroids in patients with CU, although
they are useful in clinical practice to control symptoms
[203]. A retrospective cohort study found that the use of
systemic corticosteroids in CU increased risk of corticoster-
oid-related adverse events and health care costs compared
to patients not treated with steroids [204]. Corticosteroids
should be given for short periods (3–10 days) given the un-
acceptable adverse events of their long-term use [7].
Montelukast
Recommendation. Montelukast in children with CU
may be added to a second generation H1-antistamine
if they do not control symptoms at standard dose
(Level of evidence VI. Strength of Recommendation C).
There are no paediatric studies on montelukast in CU.
In adults, some randomized trials on montelukast alone in
CSU did not improve symptoms better than H1-antista-
mine, while there was weak evidence of efficacy when it is
added to H1-antistamine [205–207]. The choice of this
drug can also be justified by its excellent safety profile.
Other therapies
Recommendation. There is insufficient data to
evaluate indication of other treatments in
paediatric CU (Level of evidence VI. Strength of
Recommendation D).
Methotrexate is a drug of uncertain efficacy in CSU,
considering the scarcity of studies concerning its efficacy
and tolerability [208, 209]. Moreover, there are no data in
children. There is no evidence of efficacy in children for
the following drugs: sulfasalazine, interferon, plasmapher-
esis, phototherapy, immunoglobulin ev, danazol, warfarin,
ac. tranexamic, hydroxychloroquine, rituximab, heparin,
anakinra, anti-TNF alpha, colchicine, miltefosine, mirtaza-
pine, camostat mesylate, mycophenolate mofetil [7, 210].
A systematic review analysed the efficacy of allergen-
specific immunotherapy in CU, including 2 very low-qual-
ity paediatric studies that would demonstrate significant
efficacy in improving urticaria symptoms [211]. Allergen-
specific immunotherapy in CU and in atopic dermatitis
[212] is supported by preliminary evidence of effectiveness
as opposed to respiratory allergies [213]. A controlled
study analysed the use of atorvastatin in combination with
an antihistamine [214], another randomized the use of
levothyroxine in euthyroid patients with positive blood
antibodies [215]. In a randomized parallel single blind
trial, performed on 88 adult patients, no significant differ-
ence was found in the improvement of CSU after the in-
jection of autologous whole blood or autologous serum or
placebo after 6 weeks of treatment [216]. A randomized
study on 24 patients with CSU, aged between 14 and 58
years old, who were treated with PUVA or with NB-UVB
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and evaluated at 20 weeks, did not find any significant dif-
ferences in the efficacy of both therapies [217]. An open
study is available on the use of vitamin D in CSU in 57 pa-
tients aged 14 to 75 years old, with vitamin D values below
30 mcg/L. They were treated with 300.000 IU/month for
3months and a significant improvement of UAS4 and
Chronic Urticaria Quality of Life Questionnaire (CU-
Q2oL) was found [218]. Therefore, vitamin D supplemen-
tation can be helpful in patients with demonstrated
vitamin D deficiency. The efficacy of a Peony derivative in
combination or not with cetirizine was examined in a ran-
domized study in patients aged between 16 and 65, with
significant results although not standardized [219]. The
effects of herbs were described in a randomized trial of pa-
tients of unknown age [220].
Question 26. Does CU have an impact on patient's
quality of life, and which is the burden of the disease
on psychological aspects? How should psychological
distress be addressed?
Recommendation
• CU affects children's quality of life and their
families. The most effective instrument to evaluate
quality of life is the care relationship. When necessary,
however, the CU-Q2oL can be useful. (Level of
evidence V. Strength of recommendation B.)
• A multidimensional strategy which includes
psychoeducational and behavioural interventions,
would be appropriate for all patients with CU. Regular
monitoring of the patient's emotional state through
periodic (every six-months) psychological counselling
can reduce maladaptive strategies, prevent or timely
identify the onset of significant psychological
problems, and intervene timely (Level of evidence VI.
Strength of Recommendation B).
• It is recommended to investigate the presence of
anxiety, depressive symptoms, isolation or stressful
events in patients with CU, as well as to evaluate any
signs of psychological or relational distress in patient's
parents and/or siblings (Level of evidence VI. Strength
of recommendation B)
• It is recommended that the multidisciplinary team
has a "psychological approach", oriented to
empathic listening, availability, clarity, and using a
shared language. (Trial Level VI Strength of
Recommendation B).
• It is recommended that referral of the patient to a
psychological consultation happens in a valid team/
patient/family relationship. Is should not be a
delegation, but a common route (Level of evidence VI.
Strength of recommendation B).
• Type of the psychoeducational approach (individual
or group) varies according to the doctor's availability
and family’s needs and availability (Level of evidence
VI Strength of recommendation B).
Psychological impact and quality of life
Several studies agree that CU is a disabling skin disease
with a very significant impact on patient’s psychological
state and quality of life. In a mixed population of chil-
dren and adults, higher levels of anxiety and depression
were found in patients with an uncertain diagnosis
[221]. The most used tool for assessing children’s quality
of life is Children’s Dermatology Life Quality Index
(CDLQ) [222]. CU-Q2oL has been recommended [7].
Unfortunately, all the studies on psychological aspects
and impact on the quality of life were carried out on
adult patients and there is very little on children. A
paediatric disease is an event that may influence the par-
ent-child relationship, becoming very important and
central in family life. Parents can experience feelings of
guilt and frustration, financial strain, inadequacy that
can be “silently” transmitted to the child, who can
perceive themselves as very ill, and create a personal
identity that revolves around the disease. In this context,
the characteristics of the family, its resources, the social
context are very important to avoid the onset of possible
experiences of diversity, limitation, fragility and non-ami-
ability in the child. Several studies reported that, in chil-
dren with CU, discomfort caused by itching, aesthetic
aspect and unpredictability of manifestations can cause, in
the children, concern about their health and some intern-
alizing symptoms, anxiety, a higher risk of depression, in a
circular reaction in which it is difficult to identify causes
and effects [126, 223, 224] .
Children with CU mainly complain about itching and
pain with emotional, behavioural and relational impair-
ment and a negative impact on quality of life [5, 222].
Perception of pain and pruritus can be influenced by
an individual emotional component, due to patient char-
acteristics, stressful events, and family attitude towards
the disease. Studies have reported that parents of pa-
tients with CU report feelings of fatigue, despair and
sleep disorders, as well as a constant time commitment
to therapy and check-ups.
Monitoring and approach of emotional/psychological
distress
Some studies have affirmed that, since children with CU
have high psychiatric morbidity, their psychological
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status should be screened by clinicians. A regular six-
monthly monitoring allows early detection of signs of
discomfort such as tension, anxiety, depressive feelings,
social isolation, somatic complaints, sleep and eating dis-
orders, bad school performance. A psychiatric evaluation
of all family members is necessary to investigate any
personal and/or couple problems, feelings of inadequacy,
guilt and inability to give attention to other children, sib-
ling rivalry because of attention focused on the child
with disease.
In order to be effective, psychological consultation must
take place within a valid and trust-based relationship be-
tween clinicians, patient and his family. The referral must
be “protected and accompanied” because the emotional
area is considered an integral part of the treatment
process. It is desirable that the first psychological consult-
ation takes place in the presence of the attending special-
ist, sharing information about the necessary therapeutic
interventions, that must be well explained to the family.
Therapeutic programs must be integrated and benefi-
cial, they can be individualized or group-based (paedia-
trician-psychologist plus any other specialists such as
dermatologist, allergist or immunologist) [225]. The
group psychoeducational intervention allows child and
his family to confront with other patients, reducing the
feeling of isolation, loneliness and diversity. The psy-
choeducational approach presupposes a holistic vision,
based on collaboration, skills increasing, coping and
mobilization of the resources of the patient and his
parents.
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